loading page

House dust mite subcutaneous immunotherapy has sustained long- term effectiveness on allergic rhinitis and asthma: a 10-year follow-up.
  • +3
  • Elena Rodriguez Plata,
  • Ariel Callero,
  • Monica Ruiz Garcia,
  • Aida Gomez Cardenosa,
  • Eva Nieto,
  • Jose Carlos García-Robaina
Elena Rodriguez Plata
Hospital Universitario Nuestra Senora de la Candelaria
Author Profile
Ariel Callero
Hospital Universitario Nuestra Senora de la Candelaria
Author Profile
Monica Ruiz Garcia
Laboratorios Leti SL

Corresponding Author:mruiz@leti.com

Author Profile
Aida Gomez Cardenosa
Laboratorios Leti SL
Author Profile
Eva Nieto
Laboratorios Leti SL
Author Profile
Jose Carlos García-Robaina
Hospital Universitario Nuestra Senora de la Candelaria
Author Profile

Abstract

Background: Maintenance doses for AIT have been recommended for at least 3 years, little data on long-term efficacy is available depending on AIT duration. To show sustained efficacy 10 years after completion of treatment with depigmented-polymerized house dust mite (dpg-pol HDM) allergen extract in adults with asthma and/or rhinoconjunctivitis. Methods: Patients included in a double-blind placebo-controlled AIT study with dpg-pol HDM allergen extract were reviewed at completion of the perennial treatment and 10 years later (10y-FU). Change in symptom and rescue medication score was the primary objective. Visual analogue scale, asthma control test (ACT) and degree of disease control were secondary objectives. A comparative analysis between patients who underwent treatment for < 3 years and ≥ 3 years was performed. Results: Data from 31 patients (mean age 38 years) were available at 10y-FU. All had asthma and 29 had rhinoconjunctivitis at baseline. Twenty-three patients were treated ≥ 3y and 8 for < 3y. Seventeen (55%) patients were asymptomatic at completion AIT completion, with significant differences for nasal, conjunctival and bronchial symptoms (p<0.0001) compared to baseline only in patients treated ≥3y. Nine (52.9%) patients remained completely asymptomatic at 10yFU , all were treated for ≥ 3 years. Moreover, significant reduction in the number of patients with rhinitis (p=0.0117), conjunctivitis (p<0.0001) and bronchial (p=0.0005) symptoms was observed at 10y-FU compared to baseline only in the ≥3y treated. Ten (32.3%) patients didn´t require any rescue medication at 10y-FU, all had been treated for ≥ 3y. ACT at 10y-FU showed a good control of asthma (median 23.5; 95% IC[22.0, 25.0]). No significant differences were observed between VAS at end of treatment compared to VAS at 10y-FU. Conclusions: Sustained clinical efficacy is achieved 10 years after completion of depigmented-polymerized HDM, however these findings were observed only if patients are treated for at least 3 years.
21 Jun 2023Submitted to Immunity, Inflammation and Disease
23 Jun 2023Submission Checks Completed
23 Jun 2023Assigned to Editor
23 Jun 2023Review(s) Completed, Editorial Evaluation Pending
28 Jun 2023Reviewer(s) Assigned
17 Aug 2023Editorial Decision: Revise Minor
29 Aug 20231st Revision Received
30 Aug 2023Submission Checks Completed
30 Aug 2023Assigned to Editor
30 Aug 2023Review(s) Completed, Editorial Evaluation Pending
30 Aug 2023Reviewer(s) Assigned
30 Aug 2023Editorial Decision: Accept